A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Trial Identifier: INS1007-211
Sponsor: Insmed
Start Date: November 2021
Primary Completion Date: November 2022
Study Completion Date: November 2022
Condition: Cystic Fibrosis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, Florida Gainesville, Florida, United States, 32610-0001
United States, Georgia Augusta, Georgia, United States, 30912-0004
United States, Illinois Glenview, Illinois, United States, 60025-7645
United States, Massachusetts Boston, Massachusetts, United States, 02115-5724
United States, Michigan Ann Arbor, Michigan, United States, 48109
United States, Missouri Saint Louis, Missouri, United States, 63101
United States, New York New York, United States, 10032-3720
United States, Ohio Cleveland, Ohio, United States, 44106-1716
United States, Ohio Cleveland, Ohio, United States, 44195-0001
United States, Oregon Portland, Oregon, United States, 97239-3011
United States, South Carolina Charleston, South Carolina, United States, 29425-8900
United States, Tennessee Nashville, Tennessee, United States, 37232-0028
United States, Texas Dallas, Texas, United States, 75390-7208
United States, Texas Tyler, Texas, United States, 75708